(0)
Study concludes that psilocybin findings should be explored further in larger studies
London, UK, April 15, 2021(NEJM) yesterday, which showed signals of positive activity in COMP360 psilocybin compared with the standard antidepressant escitalopram, for major depressive disorder (MDD).
The study was designed and conducted by a research team at Imperial College London, using COMPASS s COMP360 psilocybin.
This was an exploratory, randomised, double-blind clinical study. Its aim was to compare the efficacy and mechanisms of action of psilocybin with a six-week course of escitalopram, a selective serotonin reuptake inhibitor (SSRI), for MDD.
The study included 59 participants; 30 were randomly assigned to the psilocybin arm, and 29 to the escitalopram arm. Participants in the psilocybin arm received two doses of 25mg psilocybin three weeks apart, with psychological support delivered prior to, during and after each psilocybin administration, plus six weeks of daily placebo caps
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
New England Journal of Medicine publishes exploratory study showing signals of positive .
COMPASS Pathfinder Ltd.April 15, 2021 GMT
London, UK, April 15, 2021 (GLOBE NEWSWIRE) COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, welcomed a study published in the New England Journal of Medicine (NEJM) yesterday, which showed signals of positive activity in COMP360 psilocybin compared with the standard antidepressant escitalopram, for major depressive disorder (MDD).
ADVERTISEMENT
The study was designed and conducted by a research team at Imperial College London, using COMPASS’s COMP360 psilocybin.
New England Journal of Medicine publishes exploratory study showing signals of positive activity in COMP360 psilocybin compared with escitalopram for major depressive disorder
COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, welcomed a study published in the New England Journal of Medicine yesterday, which showed signals of positive activity in COMP360 psilocybin compared with the standard antidepressant escitalopram, for major depressive disorder . The study was designed and conducted by a research …
COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, welcomed a study published in the New England Journal of Medicine (NEJM) yesterday, which showed signals of positive activity in COMP360 psilocybin compared with the standard antidepressant escitalopram, for major depressive dis
COMPASS Pathways plc to participate in 20th Annual Needham Virtual Healthcare Conference
COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that George Goldsmith, Chairman, CEO and Co‑founder, and Lars Wilde, President, Chief Business Officer, and Co‑founder, will present a corporate update at 8:00am ET on 15 April at the 20 th Annual Needham Virtual Healthcare Conference. Members of the COMPASS …
COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that George Goldsmith, Chairman, CEO and Co‑founder, and Lars Wilde, President, Chief Business Officer, and Co‑founder, will present a corporate update at 8:00am ET on 15 April at the 20 th Annual Needham Virtual Healthcare Conference. Members of the COMPASS management team will also be holding 1:1 investor mee
COMPASS Pathfinder Ltd.: COMPASS Pathways plc to participate in 20th Annual Needham Virtual Healthcare Conference
London, UK, April 09, 2021 (GLOBE NEWSWIRE) COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that George Goldsmith, Chairman, CEO and Co-founder, and Lars Wilde, President, Chief Business Officer, and Co-founder, will present a corporate update at 8:00am ET on 15 April at the 20
th Annual Needham Virtual Healthcare Conference. Members of the COMPASS management team will also be holding 1:1 investor meetings.
A live audio webcast of the presentation will be available on the Events page of the Investors section of the COMPASS website. A replay of the webcast will be available for 30 days following the event. For more information, please visit ir.compasspathways.com.